FindMyKOL

Gaurav Shah, MD

Enriched profile

West Coast Retina Medical Group

ORCIDNone on fileNPI↗
✓ Itemized profile
Region🇺🇸 San Francisco, CA · West · United StatesSpecialtyOphthalmologyFocusMacular Degeneration (AMD)+4
Active KOLFindMyKOL type: NationalLatest publicationNone indexedOnline presenceNone verifiedPayments2021–2025NIH fundingNone on fileWhy? →

Gaurav Shah is a Macular Degeneration (AMD) physician affiliated with West Coast Retina Medical Group. ClinicalTrials.gov lists 6 registered studies with this person as an investigator.

Data verified 13 Nov 2026

Overview

Updated 17 Nov 2026

Gaurav Shah, MD, is affiliated with West Coast Retina Medical Group. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 21 companies.

  • Top research focus: Macular Degeneration (AMD)
  • 6 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 21 companies

Generated from the cited public record · current as of 17 Nov 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Macular Degeneration (AMD)2 trialsEdema2 trialsMacular Edema2 trialsRetinal Vein Occlusion2 trialsChoroidal Neovascularization1 trialEpiretinal Membrane1 trialHistoplasmosis1 trial

Research focus

OpenAlex concept fingerprint
Macular Degeneration (AMD)Macular EdemaChoroidal NeovascularizationEpiretinal MembraneRetinal Vein Occlusion

Drugs & molecules

across trials, industry payments and publications
EYLEA HDClinical trials—Industry payments99Publications—Eyleageneric · AfliberceptClinical trials—Industry payments75Publications—Ozurdexgeneric · DexamethasoneClinical trials—Industry payments33Publications—Brilliant blue GClinical trials—Industry payments15Publications—Cimerligeneric · RanibizumabClinical trials—Industry payments11Publications—Xiperegeneric · TriamcinoloneClinical trials—Industry payments11Publications—Vabysmogeneric · FaricimabClinical trials—Industry payments7Publications—Visudynegeneric · VerteporfinClinical trials—Industry payments3Publications—Inveltysgeneric · Loteprednol etabonateClinical trials—Industry payments2Publications—Yutiqgeneric · FluocinoloneClinical trials—Industry payments2Publications—CorticotropinClinical trials—Industry payments1Publications—Izervaygeneric · Avacincaptad pegolClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Regeneron Healthcare Solutions, Inc.Clinical trials—Industry payments163Dutch Ophthalmic, USAClinical trials—Industry payments29Abbvie Inc.Clinical trials—Industry payments19Carl Zeiss Meditec USA, Inc.Clinical trials—Industry payments16Allergan, Inc.Clinical trials—Industry payments15Bausch & Lomb Americas Inc.Clinical trials—Industry payments15Biogen, Inc.Clinical trials—Industry payments13Genentech USA, Inc.Clinical trials—Industry payments13Carl Zeiss Meditec, Inc.Clinical trials—Industry payments7Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments7Coherus Biosciences Inc.Clinical trials—Industry payments5Barnes Retina InstituteClinical trials4Industry payments—ANI Pharmaceuticals, Inc.Clinical trials—Industry payments3Bausch & Lomb, a division of Bausch Health US, LLCClinical trials—Industry payments3Dutch Ophthalmic Research Center (International) B.V.Clinical trials—Industry payments3Retina Research Institute, LLCClinical trials2Industry payments—Astellas Pharma US IncClinical trials—Industry payments1Beaver-Visitec International, Inc.Clinical trials—Industry payments1Harrow Eye, LLCClinical trials—Industry payments1Kala Pharmaceuticals, Inc.Clinical trials—Industry payments1Lupin Inc.Clinical trials—Industry payments1Neurotech Pharmaceuticals, Inc.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓

Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →

Clinical & industry

trials, payments and federal funding
6clinical trials

Investigator role on registered studies.

View trials ↓
21companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 13 Nov 2026

Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 13 Nov 2026

21 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    71.5%
    Vascular Endothelial Growth Factor Inhibitor71.5%
    Aflibercept100%
    Part B, office-administered≥34 patients
  • Sensory organs

    23.3%
    Corticosteroid12.4%
    Prednisolone Acetate100%
    Part D≥22 patients
    Polymyxin-class Antibacterial10.8%
    Polymyxin B Sul-Trimethoprim100%
    Part D≥20 patients
  • Cardiovascular

    5.2%
    Beta blocker5.2%
    Timolol Maleate100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

None on file yet. We only list publications we can confidently match to this person. Why? →

Background & recognition

Updated 13 Nov 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗

Editorial & leadership roles

journal and society appointments

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.